Category: Antibody Discovery

Antibodies are key components of the immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. The novel antibody therapies include different classes of antibodies, that are responsible for killing or inhibiting disease-causing agents. These therapies target proteins that are expressed on the surface of

Novel antibody therapies are chimeric proteins having antibodies attached lethal effector molecules. Currently, six of these therapies are commercially available, while around 140 molecules are under development majorly for oncological disorders. Multiple novel antibody formats have been engineered to enhance therapeutic efficacy. This has opened a new target space for the development of antibody therapeutics

Since the approval of Enbrel®, CD4-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics.[1] Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion therapeutics including  Arcalyst® (recurrent pericarditis,

Antibody-drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic / research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy / cytotoxic

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry.[1] In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025.[2] Further, within the antibody therapeutics industry, engineered

The rising demand for personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody-based therapeutics. The ‘Antibody Discovery: Services and Platforms, 2017-2027’ report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and